查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1990037

消化系统健康治疗市场：2026-2032年全球市场预测（按药物类别、给药途径、最终用户和分销管道划分）

Dyspepsia Drug Market by Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，消化不良治疗市场价值将达到 94.8 亿美元，到 2026 年将成长至 99.5 亿美元，到 2032 年将达到 136.2 亿美元，复合年增长率为 5.31%。

主要市场统计数据
基准年 2025 94.8亿美元
预计年份：2026年 99.5亿美元
预测年份 2032 136.2亿美元
复合年增长率 (%) 5.31%

为策略决策者提供关于消化不良治疗趋势的综合框架，重点关注临床进展、商业性现实和证据优先事项。

消化不良的治疗涉及临床实践、患者行为和商业策略的复杂交汇点。临床医生必须适应不断变化的诊断框架，而保险公司和采购团队则寻求既能缓解症状又具有适合长期使用的安全性的治疗方法。近年来，我们对功能性消化不良病理生理学的认识不断加深，这重新激发了人们对传统药物和新型作用机制的兴趣，促使相关人员重新评估治疗定位和价值提案。

对正在重塑消化不良医疗保健服务、商业模式和相关人员决策框架的临床、技术和政策因素进行详细分析。

由于临床、技术和政策因素的相互作用，消化不良的治疗格局正在改变。我们对胃动力和内臟高敏感性机制的理解不断加深，重新激发了研究兴趣，并因此重塑了临床医生和研发人员正在考虑的治疗方法。同时，数位健康工具和远端监测正在改变诊疗路径，它们有助于症状追踪、药物依从性支持，并促进基层医疗提供者和胃肠病学家之间的更紧密合作。

评估促进消化系统疾病治疗市场供应链多元化、价格监控和业务永续营运的贸易政策变化和关税压力。

预计到2025年，关税调整和贸易政策转变将对全球药品供应链和筹资策略带来巨大压力，包括对消化系统疾病治疗的下游影响。原料药（API）、辅料和成品的关税相关成本增加可能会扰乱生产经济，并影响供应商选择、契约製造关係和库存管理实践。为此，许多製造商正在重新审视筹资策略，实现供应商多元化，并减少对单一国家的依赖。这有助于他们应对成本波动，同时增强自身韧性。

将治疗领域、给药途径、分销管道和最终用户情况联繫起来的详细細項分析，可以製定有针对性的产品和商业策略。

细分市场分析揭示了在跨治疗领域、给药途径、分销管道和终端用户检验治疗方法时，一些微妙的性能因素会相互影响。不同药物类别之间存在差异，包括针对症状的制酸剂、H2受体拮抗剂、用于改善运动功能障碍的促动力药物以及抑制胃酸分泌的质子帮浦阻断剂。每种药物类别都有其独特的安全性、耐受性和长期使用方面的考量，这些都会影响处方和患者依从性。同样，给药途径的差异也会影响患者的偏好和遵从性。发泡颗粒剂具有给药柔软性、起效迅速的优点；液体剂型适用于儿童和吞嚥困难的患者；而片剂因其方便性和剂量精确性，仍然是标准选择。

对美洲、欧洲、中东和非洲以及亚太地区的临床报销和供应趋势进行全面评估，以指南市场准入。

区域特征影响消化不良治疗药物的研发、应用和推广，每个地区在监管、报销和医疗基础设施方面都存在独特的考量。在美洲，以疗效为导向的合约和健全的门诊体系促进了那些在患者报告结局（PRO）和耐受性方面展现出显着改善的治疗方法的快速应用。该地区的临床实践得益于支付方和医疗服务提供者组成的整合网络，以及私营部门的积极参与，这些因素共同影响着药物的纳入和处方行为。

策略竞争格局评估，重点在于优化现有产品组合、创新伙伴关係以及基于证据的消化不良治疗差异化。

消化不良领域的竞争格局呈现出两极化的态势：既有老牌製药公司维持现有产品组合，也有规模较小、锐意创新的公司寻求透过新的作用机制和配方改进实现差异化。老牌製药公司持续投资于配方改进、真实世界数据（RWE）收集以及患者支持项目，以保持产品的相关性和患者依从性。同时，生物技术和专科公司则致力于针对尚未解决的病理学难题，利用早期临床数据和生物标记策略来降低研发过程中的风险。

为加强供应韧性、加速证据产生、优化跨通路商业化以实现治疗方法。

产业领导企业应优先采取策略措施，以增强韧性、加快实证医学证据的产生并改善以病人为中心的医疗服务取得。首先，供应链多元化、在地化生产或建立合作生产伙伴关係，将有助于降低关税衝击和物流中断带来的风险，同时提高前置作业时间的可靠性。其次，投资于可操作的研究和真实世界证据，收集患者报告结局（PRO）、耐受性和依从性等信息，将有助于提高支付方的参与度，并促进不同医疗保健系统将处方集纳入处方。

透明的调查方法，结合对关键相关人员的访谈、二手文献的整合以及资料检验，确保了检验和可操作的见解。

本分析整合了来自一手和二手调查的结果，旨在对消化不良的治疗和市场动态提供全面的视角。一手调查包括对临床医生、支付方代表、采购负责人和供应链专家的结构化访谈，以收集关于处方行为、报销重点和物流限制等方面的实际观点。除了这些定性讨论外，还审查了监管指南、临床试验註册资讯以及公开的安全资讯和附加檔变更，以确保与当前的实践和政策趋势保持一致。

强调临床差异化、生产灵活性和以支付方为中心的证据整合的策略结论，旨在促进可持续的治疗取得。

总之，目前消化不良治疗的现状呈现出临床认识不断演进、商业性需求不断变化以及营运压力不断增加的特点，这些因素共同重塑了研发方和支付方的策略重点。成功应对这一局面需要科学严谨性、灵活的供应链设计以及与支付方期望和患者体验指标相符的针对性证据的建构。透过将临床差异化与可操作的交付模式以及涉及支付方的价值论点相结合，相关人员可以显着提高治疗普及率和长期用药依从性，同时降低政策和贸易中断带来的风险。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：消化不良治疗药物市场：依药物类别划分

  • 制酸剂
  • H2受体拮抗剂
  • 胃肠动力刺激剂
  • 质子帮浦阻断剂

第九章：消化不良治疗药物市场：依给药途径划分

  • 发泡颗粒
  • 口服液
  • 口服锭剂

第十章：消化不良治疗市场：依最终使用者划分

  • 诊所
  • 居家照护
  • 医院

第十一章：消化不良治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：消化不良治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：消化不良治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：消化不良治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国消化系统疾病治疗市场

第十六章：中国消化不良治疗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-5D693B46BAC4

The Dyspepsia Drug Market was valued at USD 9.48 billion in 2025 and is projected to grow to USD 9.95 billion in 2026, with a CAGR of 5.31%, reaching USD 13.62 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.48 billion
Estimated Year [2026] USD 9.95 billion
Forecast Year [2032] USD 13.62 billion
CAGR (%) 5.31%

Comprehensive framing of dyspepsia therapeutic dynamics emphasizing clinical evolution commercial realities and evidence priorities for strategic decision-makers

Dyspepsia management traverses a complex intersection of clinical practice, patient behavior, and commercial strategy. Clinicians continue to adapt to evolving diagnostic frameworks, while payers and procurement teams seek interventions that balance symptomatic relief with safety profiles suitable for chronic use. Over recent years, advances in understanding functional dyspepsia pathophysiology have translated into renewed interest across both legacy classes and novel mechanisms, prompting stakeholders to reassess therapeutic positioning and value propositions.

From a commercial perspective, the landscape is shaped by treatment heterogeneity, patient adherence challenges, and varied routes of administration that influence prescribing patterns. Uptake of newer therapies often hinges on clear differentiation in real-world tolerability and demonstrable improvements in patient-reported outcomes. Consequently, manufacturers and policymakers increasingly emphasize evidence generation beyond traditional efficacy endpoints, integrating health economics, quality-of-life metrics, and pragmatic trial data to support product adoption in clinical settings.

Transitioning from clinical insights to actionable strategy requires clarity on regulatory expectations, formulary dynamics, and distribution pathways. This introduction establishes a foundation for subsequent sections by framing key drivers that influence therapeutic development, commercialization, and stakeholder decision-making within the dyspepsia domain.

Deep analysis of converging clinical technological and policy drivers reshaping dyspepsia care delivery commercial models and stakeholder decision frameworks

The dyspepsia treatment landscape is undergoing transformative shifts driven by converging clinical, technological, and policy forces. Advances in mechanistic understanding of gastric motility and visceral hypersensitivity have catalyzed renewed research interest, which in turn is reshaping the therapeutic mix under consideration by clinicians and developers. Simultaneously, digital health tools and remote monitoring are changing care pathways by facilitating symptom tracking, adherence support, and tighter integration between primary care and gastroenterology specialists.

On the regulatory and reimbursement front, payers are increasingly prioritizing real-world evidence and patient-centered outcomes, compelling manufacturers to design post-approval studies and value-based contracting models. Parallel to these changes, manufacturing and distribution innovations - such as alternative formulations and extended-release technologies - are enabling more patient-friendly administration profiles, which has implications for persistence and long-term safety management. Collectively, these factors are redefining competitive advantage, where differentiation is achieved not only through molecular innovation but also through strategic choices in evidence generation, patient engagement, and channel optimization.

In this context, successful stakeholders will be those who align R&D priorities with pragmatic clinical needs, integrate digital and pharmaceutical solutions to support adherence, and proactively engage payers to translate clinical benefit into sustainable access pathways.

Assessment of trade policy shifts and tariff pressures catalyzing supply chain diversification pricing scrutiny and operational resilience across dyspepsia therapeutics

Anticipated tariff adjustments and trade policy shifts through 2025 are exerting material pressure on global pharmaceutical supply chains and procurement strategies, with downstream consequences for dyspepsia therapeutics. Tariff-related cost increments for APIs, excipients, and finished dosage forms introduce variability in manufacturing economics that can influence supplier selection, contract manufacturing relationships, and inventory management practices. In response, many manufacturers are recalibrating sourcing strategies to diversify supplier bases and reduce dependency on single-country sourcing, thereby enhancing resilience while managing cost volatility.

The cumulative impact of tariffs is also observable through adjustments to pricing negotiations and tender bidding behavior in both public and private procurement channels. Buyers are increasingly scrutinizing landed cost components and seeking transparency around supply chain margins, which has led to longer lead times on contract awards and a preference for suppliers able to demonstrate robust supply continuity plans. For smaller innovators, the tariff environment can complicate market entry by raising barriers to competitive pricing unless offset by premium clinical differentiation or strategic partnerships.

Moreover, logistic bottlenecks and customs delays associated with tariff implementation amplify the need for robust demand forecasting and buffer inventory strategies. Companies are therefore investing in regional manufacturing and distribution hubs, as well as in enhanced trade compliance capabilities, to mitigate exposure to tariff-related disruptions. The net effect is a recalibration across the value chain toward diversified sourcing, operational flexibility, and more sophisticated commercial contracting to preserve access while managing margin pressures.

In-depth segmentation analysis linking therapeutic class administration pathways distribution channels and end-user contexts to inform targeted product and commercial strategies

Segmentation analysis reveals nuanced performance drivers when therapies are examined across therapeutic class, route of administration, distribution channels, and end user. When viewed through the lens of drug class, differentiation emerges between symptom-targeting antacids, H2-receptor antagonists, prokinetics that address motility dysfunction, and proton pump inhibitors that deliver acid suppression; each class carries unique safety, tolerability, and chronic-use considerations that influence prescribing and patient persistence. Differences in route of administration similarly shape patient preference and adherence, with effervescent granules offering dosing flexibility and rapid onset, oral liquids providing suitability for pediatric or dysphagia-prone populations, and oral tablets remaining the default for convenience and dosing accuracy.

Distribution channel dynamics are equally consequential, as hospital pharmacy procurement prioritizes formulary compatibility and inpatient continuity while online pharmacy models emphasize convenience, subscription services, and direct-to-patient logistics; retail pharmacy remains an essential point-of-care for OTC access and pharmacist-led counselling. End-user segmentation further nuances market engagement, as clinics focus on diagnostic clarity and follow-up, home care settings prioritize ease of use and adherence support, and hospitals concentrate on acute management and integration with inpatient gastroenterology services. Taken together, these intersecting segmentation axes inform product development priorities, patient support programming, and channel-specific commercial tactics that are essential for sustained therapeutic uptake.

Comprehensive appraisal of regional clinical reimbursement and supply dynamics across the Americas Europe Middle East & Africa and Asia-Pacific to guide market entry

Regional nuances shape how dyspepsia therapies are developed, adopted, and delivered, with each geographic zone presenting distinct regulatory, reimbursement, and healthcare infrastructure considerations. In the Americas, emphasis on outcomes-based contracting and a strong outpatient care ecosystem supports rapid adoption of therapies that demonstrate meaningful improvements in patient-reported outcomes and tolerability profiles. Clinical practice in this region is supported by integrated payer-provider networks and significant private-sector participation, which together influence formulary decisions and prescribing behavior.

Across Europe Middle East & Africa, heterogeneity is pronounced: European markets feature centralized HTA processes and rigorous evidence requirements that favor therapies with demonstrable long-term benefit, while Middle Eastern and African markets vary widely from advanced tertiary centers to constrained-resource settings where affordability and supply chain reliability are paramount. Stakeholders operating in this region must navigate diverse regulatory frameworks and procurement mechanisms, as well as tailored evidence strategies to secure adoption across public and private payers.

In Asia-Pacific, rapid urbanization and expanding primary care access are driving increased diagnosis rates and higher demand for symptomatic management. Markets in this region are characterized by a blend of strong generics penetration, growing specialty care capacity, and an appetite for innovative formulations that enhance adherence. Regional manufacturing capabilities and intra-regional trade agreements also influence supply dynamics, making localized production and supply partnerships strategic priorities for market entry and scale.

Strategic competitive landscape evaluation highlighting legacy portfolio optimization innovation partnerships and evidence-driven differentiation across dyspepsia therapeutics

Competitive dynamics in the dyspepsia domain reflect a mix of established pharmaceutical players maintaining legacy portfolios and smaller innovators seeking differentiation through novel mechanisms or formulation improvements. Established manufacturers continue to invest in incremental formulation advances, real-world evidence generation, and patient support programs to sustain product relevance and adherence. At the same time, biotech and specialty firms are pursuing targeted approaches that address unmet pathophysiology, leveraging early-phase clinical data and biomarker strategies to de-risk development pathways.

Strategic partnerships and licensing deals remain central to company growth strategies, enabling asset owners to access broader distribution networks, enhance manufacturing scale, and accelerate clinical development through shared expertise. Additionally, a growing emphasis on lifecycle management means that firms are exploring label expansions, pediatric formulations, and combination approaches to extend therapeutic utility. Competitive advantage increasingly rests on integrating robust safety and tolerability narratives with clear evidence of real-world patient benefit, supported by comprehensive patient assistance and digital adherence programs that demonstrate improved outcomes in routine care.

Actionable strategic recommendations to enhance supply resilience accelerate evidence generation and optimize channel specific commercialization for sustained therapeutic adoption

Industry leaders should prioritize strategic actions that strengthen resilience, accelerate evidence generation, and enhance patient-centric access. First, diversifying supply chains and establishing regional manufacturing or co-manufacturing partnerships will reduce exposure to tariff shocks and logistical disruptions while improving lead time reliability. Second, investing in pragmatic studies and real-world evidence generation that capture patient-reported outcomes, tolerability, and adherence will support payer engagement and formulary positioning across diverse health systems.

Moreover, optimizing commercial strategy requires tailoring distribution approaches to channel-specific needs: aligning hospital formulary teams with inpatient evidence, enhancing online pharmacy fulfilment and subscription models for chronic therapy continuity, and empowering retail pharmacists with tools for counselling and adherence support. Companies should also explore value-based contracting where appropriate, tying reimbursement to demonstrable improvements in clinical and patient-centered metrics. Finally, incorporating digital adherence tools, nurse-led support programs, and clear patient education into product launch plans will materially improve persistence and patient satisfaction, thereby reinforcing the clinical and commercial case for durable adoption.

Transparent research methodology integrating primary stakeholder interviews secondary literature synthesis and data triangulation to ensure validated actionable insights

This analysis synthesizes primary and secondary research inputs to deliver a robust view of dyspepsia therapeutics and market dynamics. Primary inputs included structured interviews with clinicians, payer representatives, procurement officers, and supply chain experts to capture frontline perspectives on prescribing behavior, reimbursement priorities, and logistics constraints. These qualitative discussions were complemented by a review of regulatory guidance, clinical trial registries, and publicly accessible safety and labeling changes to ensure alignment with current practice and policy trends.

Secondary research encompassed peer-reviewed literature on pathophysiology and treatment outcomes, industry white papers, and databases tracking approvals and formulation innovations. Data triangulation across sources was applied to validate thematic findings, and sensitivity checks were performed to test assumptions around supply chain responses and payer receptivity. Throughout the research process, emphasis was placed on contemporaneous evidence, stakeholder validation, and transparent documentation of source provenance to ensure that conclusions are actionable and grounded in the most relevant available information.

Strategic conclusion emphasizing integration of clinical differentiation manufacturing agility and payer focused evidence to drive durable therapeutic access

In closing, the dyspepsia therapeutics landscape is characterized by evolving clinical understanding, shifting commercial imperatives, and operational pressures that together redefine strategic priorities for developers and payers. Successful navigation requires a combination of scientific rigor, flexible supply chain engineering, and focused evidence generation that aligns with payer expectations and patient experience metrics. By integrating clinical differentiation with pragmatic delivery models and payer-engaged value demonstration, stakeholders can materially improve uptake and long-term adherence while mitigating exposure to policy and trade disruptions.

Looking ahead, the most resilient organizations will be those that translate mechanistic insight into patient-centered formulations and service models, invest in localized manufacturing and distribution arrangements, and engage proactively with payers through real-world evidence to secure durable access. The conclusion underscores the imperative for cross-functional collaboration across R&D, commercial, and supply chain teams to convert insight into sustained clinical and commercial value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dyspepsia Drug Market, by Drug Class

  • 8.1. Antacids
  • 8.2. H2-Receptor Antagonists
  • 8.3. Prokinetics
  • 8.4. Proton Pump Inhibitors

9. Dyspepsia Drug Market, by Route Of Administration

  • 9.1. Effervescent Granule
  • 9.2. Oral Liquid
  • 9.3. Oral Tablet

10. Dyspepsia Drug Market, by End User

  • 10.1. Clinic
  • 10.2. Home Care
  • 10.3. Hospital

11. Dyspepsia Drug Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Dyspepsia Drug Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Dyspepsia Drug Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Dyspepsia Drug Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Dyspepsia Drug Market

16. China Dyspepsia Drug Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. AstraZeneca PLC
  • 17.7. Bayer AG
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. Cipla Limited
  • 17.10. Dr. Reddy's Laboratories Ltd.
  • 17.11. Eisai Co., Ltd.
  • 17.12. GlaxoSmithKline PLC
  • 17.13. Hikma Pharmaceuticals PLC
  • 17.14. Johnson & Johnson
  • 17.15. Merck & Co., Inc.
  • 17.16. Novartis AG
  • 17.17. Pfizer Inc.
  • 17.18. Sanofi S.A.
  • 17.19. Sun Pharmaceutical Industries Ltd.
  • 17.20. Takeda Pharmaceutical Company Limited
  • 17.21. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DYSPEPSIA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DYSPEPSIA DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DYSPEPSIA DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DYSPEPSIA DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DYSPEPSIA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY H2-RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY H2-RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY H2-RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROKINETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROKINETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROKINETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY EFFERVESCENT GRANULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY EFFERVESCENT GRANULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY EFFERVESCENT GRANULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ORAL LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ORAL LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ORAL LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ORAL TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. MIDDLE EAST DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 78. AFRICA DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. ASEAN DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. GCC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GCC DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. GCC DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. GCC DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. GCC DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPEAN UNION DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. BRICS DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. G7 DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. G7 DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. G7 DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. G7 DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. G7 DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. NATO DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NATO DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. NATO DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. NATO DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. NATO DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA DYSPEPSIA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA DYSPEPSIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. CHINA DYSPEPSIA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. CHINA DYSPEPSIA DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. CHINA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)